Exjade: improved bioavailability for new presentation

Exjade (deferasirox) is now available as a film-coated tablet, a strength-adjusted formulation of deferasirox with higher bioavailability than Exjade dispersible tablets.

As a result of its improved bioavailability the dose for the film-coated tablet is 30% lower than that of the dispersible tablet. Accordingly, the film-coated tablet is available in lower strengths than the dispersible tablet (90mg, 180mg and 360mg versus 125mg, 250mg and 500mg, respectively).

As a risk mitigation measure to avoid medication errors, and in agreement with the European Medicines Agency, Novartis plans to discontinue Exjade dispersible tablets in the UK at the end of June 2017.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases